Details for New Drug Application (NDA): 018655
✉ Email this page to a colleague
NDA 018655 describes NORPACE CR, which is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. Additional details are available on the NORPACE CR profile page.
The generic ingredient in NORPACE CR is disopyramide phosphate. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
The generic ingredient in NORPACE CR is disopyramide phosphate. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
Summary for 018655
| Tradename: | NORPACE CR |
| Applicant: | Pfizer |
| Ingredient: | disopyramide phosphate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 018655
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NORPACE CR | disopyramide phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 018655 | NDA | Pfizer Laboratories Div Pfizer Inc | 0025-2732 | 0025-2732-31 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31) |
| NORPACE CR | disopyramide phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 018655 | NDA | Pfizer Laboratories Div Pfizer Inc | 0025-2742 | 0025-2742-31 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jul 20, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | Jul 20, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
